Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease

Eli Lilly (LLY) PT Raised to 'Street High' $300 at Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to a "Street High" $300.00 (from $245.00) while maintaining an Overweight rating after the FDA has granted its Alzheimer's disease drug donanemab Breakthrough Therapy Designation.

Eli Lilly (LLY) PT Raised to $250 at Mizuho Securities as Donanemab Granted Breakthrough Therapy Designation

Mizuho Securities analyst Vamil Divan raised the price target on Eli Lilly (NYSE: LLY) to $250.00 (from $217.00) while maintaining a Buy rating.

The analyst commented, "Lilly has answered one of the most pressing questions in our coverage, announcing the FDA has granted its Alzheimer's disease drug... More

Biogen (BIIB) declines 3.5% after Lilly's (LLY) donanemab receives FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease

Biogen (NASDAQ: BIIB) declines 3.5% after Lilly's (NYSE: LLY) donanemab receives FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease